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Fetal growth is determined by the feto-placental genome interacting with the maternal in utero environment.
Failure of this interplay leads to poor placental development and fetal growth restriction (FGR), which is associated with
future metabolic disease. We investigated whether whole genome methylation differences existed in umbilical cord
blood and placenta, between gestational-matched, FGR, and appropriately grown (AGA) neonates. Using the Inﬁnium
HumanMethylation450 BeadChip, we found that DNA from umbilical cord blood of FGR born at term (n D 19) had 839
differentially methylated positions (DMPs) that reached genome-wide signiﬁcance compared with AGA (n D 18). Using
gestational age as a continuous variable, we identiﬁed 76,249 DMPs in cord blood (adj. P < 0.05) of which 121 DMPs
were common to the 839 DMPs and were still evident when comparing 12 FGR with 12 AGA [39.9 § 1.2 vs. 40.0 § 1.0
weeks (mean § SD), respectively]. A total of 53 DMPs had a b methylation difference >10% and 25 genes were co-
methylated more than twice within 1000 base pairs. Gene Ontology (GO) analysis of DMPs supported their involvement
in gene regulation and transcription pathways related to organ development and metabolic function. A similar proﬁle
of DMPs was found across different cell types in the cord blood. At term, no DMPs between FGR and AGA placentae
reached genome-wide signiﬁcance, validated with an external dataset. GO analysis of 284 pre-term, placental DMPs
associated with autophagy, oxidative stress and hormonal responses. Growth restricted neonates have distinct DNA
methylation proﬁles in pre-term placenta and in cord blood at birth, which may predispose to future adult disease.
Introduction
Fetal growth restriction, defined as an estimated fetal weight
<10th customized centile for gestational age and adjusted for
maternal weight, height, parity, and ethnicity, is a major cause of
neonatal morbidity and mortality, associated with childhood
neurocognitive delay and metabolic and cardiovascular disease in
later life.1-3 To fulfill its growth potential, a fetus must assimilate
an adequate nutritional supply from its mother across the
placenta. This process is governed by a complex interplay
between the feto-placental genome and the maternal environ-
ment.4 In low-income nations, environmental influences on fetal
growth are predominantly related to poor maternal nutrition,
chronic disease or infections.5 In high-income nations, fetal
growth is more commonly compromised by poor placental
development.6
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Poor placental development affects approximately 4–7% of all
first time pregnancies and is often associated with the maternal
gestational syndrome preeclampsia, which is characterized by
maternal hypertension and proteinuria.7 Inadequate placental
invasion may be due to adverse immune events at the maternal-
placental interface and impaired oxygen sensing by the pla-
centa.8,9 In these circumstances, high resistance to blood flow in
utero-placental arteries pre-dates the onset of FGR.6 Inadequate
placental development might then lead to epigenetic change in
the under nourished fetus. An example of this sequence of events
has been observed in a rodent model when uterine artery blood
flow was artificially reduced during pregnancy.10 As a conse-
quence, the growth restricted offspring developed diabetes in
adulthood, associated with reduced pancreatic b cell mass.10
These events were associated with DNA methylation and reduced
expression of PDX1, a transcription factor critical to pancreatic
cell development.10
A genome wide approach has been taken to investigate meth-
ylation differences between 5 FGR and 5 AGA offspring, using
hematopoietic CD34C stem cells isolated from umbilical cord
blood.11 In FGR offspring, there was a low level of methylation
difference (6%) in a promoter of HNF4A, a gene associated with
maturity onset diabetes of the young (MODY). Altered methyla-
tion status of selected candidate genes in umbilical cord tissue
has also been correlated with later life phenotype.12 However,
these findings have not been reproduced in prospectively col-
lected umbilical cord blood, or placental samples from babies
born with growth restriction, or across a range of birth weights
investigated in later life.13-15 Furthermore, gestational age at
delivery has a powerful effect on fetal and placental methylation
status,16,17 which has not always been considered in earlier stud-
ies of FGR offspring.
Genetic factors inherited from either parent also influence pla-
cental development and fetal growth.18,19 Gene variants associ-
ated with insulin resistance are associated with reduced fetal
growth and provide a potential genetic link between low birth
weight and future risk of type-2 diabetes.20 Other genes have
conflicting influences on placental development and fetal growth
according to their parent of origin. Genomic imprinting
describes monoallelic expression of a gene following epigenetic
silencing of the other allele.21 For example, hypomethylation of
CpG sites on imprinting control region 1 (ICR1) of 11p15
reduces expression of IGF2 and leads to reduced fetal growth,
whereas hypermethylation of ICR1 increases expression of IGF2
and is associated with fetal overgrowth.22 Fetal growth restriction
secondary to known imprinted gene disorders are however rare
and do not explain the majority of FGR seen in the developed
world.
In order to discover novel DNA methylation differences asso-
ciated with FGR in the absence of maternal and fetal disease and
in gestational age-matched subjects, we conducted a case-control
study that identified otherwise healthy pregnant women with
either FGR (cases) or appropriately grown offspring (AGA; con-
trols). We used the Infinium HumanMethylation450
BeadChip to discover differences in the whole methylome
(450,000 CpG sites in 99% of genes) of umbilical cord blood
and placentae from cases and controls. After controlling for gesta-
tional age, we identified the most differentially methylated posi-
tions between FGR and AGA offspring and recognized that
DMPs were consistent across different cord blood cell types.
Gene ontology (GO) pathway analysis associated these DMPs
with gene regulation and transcription pathways related to organ
development and metabolic function. These novel DNA methyl-
ation profiles provide a robust platform for further investigation
into their role in the fetal origins of adult diseases.
Results
Participant phenotype
Fetal growth restricted offspring identified in utero were con-
firmed at birth (FGR; 1.9% § 2.3%, customized birth weight
centile) and compared with appropriately grown for gestational
age offspring (AGA; 51.8% § 30.5%, customized centile). Ret-
rospective review of fetal ultrasound scans at 20–22 weeks gesta-
tion showed that 90% (26/29) of mothers later identified with
FGR offspring had high resistance to utero placental blood flow.
No abnormal recording of utero-placental blood flow was made
at 20–22 weeks in pregnancies that went on to have AGA
offspring.
Mothers of both cases and controls met the study inclusion
criteria and were of similar age, body mass index (BMI) and par-
ity, and did not smoke (Table 1; see Materials and Methods).
Fathers of FGR offspring were more insulin resistant, as
judged by fasting HOMA IR, and had larger waist circumfer-
ences compared with fathers of AGA offspring (Table 1).
Table 1a. Baseline characteristics of the parents according to offspring birth weight. (AGA, appropriately grown for gestational age, or FGR, fetal growth
restriction).
AGA mothers (mean § SD) AGA fathers (mean § SD) FGR mothers (mean § SD) FGR fathers (mean § SD)
Number of parents 24 24 29 29
Age (years) 31.9 § 3.98 33.8 § 4.7 32.8 § 2.98 34.8 § 5.3
BMI (kgm-2) 23.7 § 3.5 25.7 § 3.2 23.4 § 3.6 27.1 § 2.8
Smoker 0 6 (25%) 0 9 (31%)
Abdominal circumference (cm) 92.1 § 7.7 94.8 § 7.1
Insulin resistance (HOMA index) 0.6 § 0.22 1.1 § 0.46
Maternal parity Primigravid, n D 21 (77%) Primigravid, n D 25 (86%)
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Differentially methylated positions in cord blood
and placenta from growth restricted offspring compared
with appropriately grown offspring
Initial analysis included 45 umbilical cord blood samples
(FGR n D 27 and AGA n D 18) and 45 placental samples (FGR
n D 23 and AGA n D 22). Differentially methylated positions
(DMPs) were identified using t test-based statistics in the Limma
package provided by Bioconductor 2.11.23 Adjustment for
genome-wide significance was performed using a False Discovery
Rate (FDR) with a threshold p value for DMPs of <0 .05.24 Irre-
spective of gestational age, there were 553 differently methylated
positions in cord blood and 453 DMPs in placenta that reached
genome wide significance between all FGR and AGA offspring
(adj. P < 0.05). As all AGA offspring were born at term, but
only 19/27 FGR offspring, it was possible
that these DMPs were influenced by gesta-
tional age.
Effect of gestational age on umbilical
cord blood DMPs between FGR and AGA
offspring
We compared genome-wide methyla-
tion differences between FGR cases (n D
19) with AGA controls (n D 18) that only
delivered >255 d (36.4 weeks). This analy-
sis yielded 839 DMPs in the cord blood
between FGR and AGA offspring, of
which the majority (86%) were hyperme-
thylated (Fig. 1). From the original 553
cord blood DMPs, 371 DMPs (67%) were
also common to the 839 term DMPs and
may therefore be secondary to fetal growth
restriction, rather than the effect of gesta-
tional age.
To further elucidate the effect of gesta-
tional age on DMPs between FGR and
AGA cord blood, we ran a linear model on
all cord blood samples (FGR and AGA)
using gestational age as a continuous
variable. Across the gestational age range (202 d to 299 days)
there were 76,249 DMPs in cord blood (adjusted P < 0.05).
The majority of DMPs were characterized by hypomethylation
(68%), an assessment that was heavily influenced by samples
from pre-term FGR offspring.
We then compared the 839 DMPs evident between FGR and
AGA offspring at term with the 76,249 DMPs found in the ges-
tational age cord blood model and identified 121 DMPs that
were common to both. We compared the direction of methyla-
tion of these 121 DMPs from both groups and found that in all
cases their direction of methylation was identical. Furthermore,
the same 121 DMPs were still evident when comparing 12 FGR
and 12 AGA offspring that were more exactly matched for gesta-
tional age (279.1 § 8.3 vs. 280.3 § 7.2 days, respectively).
Table 1b. Pregnancy characteristics according to offspring birth weight (FGR or AGA), nature of samples analyzed (cord blood or placenta), and gestational
age at birth (all samples, or term > 255 d gestation). Results expressed as mean § SD
All AGA offspring (mean § SD) All FGR offspring (mean § SD) Term FGR offspring (mean § SD)
CORD BLOOD
Number of samples 18 27 19
Birth weight (grams) 3634 § 369 2065 § 770 2487 § 420
Customized centile (%) 51.8 § 30.5 1.9 § 2.3 2.6 § 2.3
Gestation (range) days 285 (272–299) 258 (202–293) 272 (256–293)
Baby sex Male, n D 9 Female, n D 9 Male, n D 9 Female, n D 18 Male n D 7 Female n D 12
PLACENTA
Number of samples 23 22 15
Birth weight (grams) 3614 § 361 2011 § 710 2428 § 342
Customized centile (%) 47.6 § 28.6 1.8 § 2.3 2.3 § 2.0
Gestation (range) days 285 (266–300) 257 (202–286) 272 (256–286)
Baby sex Male, n D 11 Female, n D 12 Male, n D 9 Female, n D 13 Male, n D 6 Female, n D 9
Mode of delivery
(term-pregnancies only)
Vaginal, n D 18 (75%)
Caesarean section, n D 6
Vaginal, n D 12 (66.7%)
Caesarean section, n D 6
Figure 1. Volcano plot showing differentially methylated positions in umbilical cord blood
between growth restricted (FGR) and appropriately grown offspring (AGA) at term gestation.
b values are plotted against log P values. Hypermethylated positions are shown in blue and hypo-
methylated positions in yellow. A bmethylation value of 10% is represented as 0.1.
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We also compared our results to another study of a separate
cohort of AGA offspring that investigated DMPs within whole
cord blood between 32–43 weeks gestation.16 Using the Human-
Methylation27 BeadChip, 25 DMPs were identified in whole
umbilical cord blood, related to gestational age. None of these 25
gestational age-related DMPs were present in our 121 FGR cord
blood DMPs at term. This observation does not diminish the
possibility that the 121 DMPs relate to fetal growth rather than
gestational age.
Effect of cell type on umbilical cord blood DMPs between
FGR and AGA offspring
We investigated whether the 839 DMPs between FGR and
AGA might be due to differences in cellular composition of
umbilical cord blood. We downloaded 450K data from the pub-
licly available database Marmal-aid,25 which incorporates data
from multiple studies that has been normalized and quality con-
trolled. Data was available on circulating cell subtypes identified
as CD4, CD14, CD8, CD19, CD56, peripheral blood leuco-
cytes, whole blood or peripheral blood mononuclear cells from
109 different samples. We plotted the 839 different probes for
the 109 different samples and grouped the samples into their cel-
lular subtypes (Fig. 2). Overall, there was very little difference in
methylation between the 839 DMPs according to cell subtype.
This is portrayed as similar color profiles for each of the cell types
(blue, yellow, and green) that correspond to the level of b meth-
ylation (far column) of the 839 probes (Fig. 2).
In order to identify whether there was a pattern of methyla-
tion within a single cell subtype, we plotted the 839 DMPs
between FGR and AGA in cord blood (second column, Fig. 2).
There was no such correlation with a single cell subtype, which
supports the conclusion that DMPs between FGR and AGA in
cord blood are unlikely to be due to different cell proportions.
Leucocyte number is increased in neonates compared with
adults, but the absolute number of CD4 and CD19 lymphocytes
or dendritic cells is not different between pre-term or term neo-
nates.26 The absolute CD14 monocyte count is lower in very
pre-term neonates compared with late pre-term and term neo-
nates, but the relative frequency of CD14 monocyte cells is not
different, at around 3.5% of all leucocytes.26
Identity of most differentially methylated positions between
FGR and AGA offspring in umbilical cord blood
We stratified umbilical cord blood DMPs between FGR and
AGA offspring born at term, according to their degree of methyl-
ation difference. Of the 839 DMPs, 304 had a bmethylation dif-
ference of >5% and 53 DMPs had a b methylation value
difference of >10% (Table 2a). The majority of DMPs with a b
methylation >10% were hypermethylated (41/53, 77%;
Table 2a) and 8/53 were hypomethylated >-10% (Table 2b). Of
the 839 DMPs that were identified on Ref-seq annotated genes,
658 DMPs were within 1000 bp of each other and 25 of these
DMPs were co-methylated in the same direction. Out of the 53
most methylated DMPs, 8 were co-methylated in the same direc-
tion. These included C5orf39 that had 4 DMPs, FOXP1 and
NRN1 that had 3 DMPs, while RIOK3 had 2 DMPs within 5
base pairs with b methylation values of C11 and C17%
(Table 2a).
We also include the M value, calculated
as the log2 ratio of the intensities of methyl-
ated versus unmethylated probes. 27 The
top M values did not exactly correlate with
the b values, but we have categorized the
most differentially methylated CpG sites
according to b value difference, which
reflect biological activity, while M value
difference more accurately assess statistical
difference. (Table 2a and b).
Potential role of SNPs influencing
DMPs
Underlying genetic polymorphisms can
influence differences in methylation of
CpG sites.28 We assessed the potential
influence of SNPs on DNA methylation,
by cross-referencing the 53 DMPs within
term cord blood that had a b value differ-
ence of >10% with more than 150,000
SNPs in the Illumina database of SNPs
known to influence methylation (http://sup
port.illumina.com/downloads/infinium_hd_
methylation_snp_list.ilmn). We found 13
hypermethylated and hypomethylated posi-
tions in close proximity to SNPs. These
included a hypomethylated CpG site (b
Figure 2. Heat map of the 839 DMPs between FGR and AGA in circulating cord blood cell subtypes
identiﬁed as CD4, CD14, CD8, CD19, CD56, peripheral blood leucocytes, whole blood or peripheral
blood mononuclear cells from 109 different samples. 450K data from a publicly available database
Marmal-aid (http://marmal-aid.org.)25 (see methods). There is very little difference in methylation
between the 839 DMPs according to cell subtype. This is portrayed as similar color proﬁles for
each of the cell types (blue, yellow and green) that correspond to the level of b methylation (far
column) of the 839 probes.
www.tandfonline.com 53Epigenetics
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 08
:35
 24
 M
arc
h 2
01
5 
Table 2a. The most methylated DMPs (b value >C10%) in umbilical cord blood from FGR compared with AGA offspring. Columns show CG identifying site,
chromosome number, chromosome coordinate, gene identiﬁer, chromosome number, methylation b value, and adjusted P value for difference in mean
b value between FGR and AGA offspring and M value
ID Hypermethylated Positions CHR MAPINFO UCSC Ref Gene b value difference P value M value difference
cg25418748 5 178977236 RUFY1 0.17 4.10E-08 ¡0.88
cg20796556 18 21032774 RIOK3 0.17 4.32E-08 ¡1.02
cg17724814 1 155881358 RIT1 0.16 8.41E-07 ¡0.99
cg07979357 19 14142353 IL27RA 0.15 4.30E-08 ¡0.92
cg01769037 6 15246613 JARID2 0.14 2.36E-07 ¡1.08
cg22256960 15 77711686 0.14 2.70E-06 ¡0.90
cg19857457 18 47018947 RPL17;SNORD58A 0.14 1.92E-07 ¡0.90
cg27069263 2 55278118 RTN4 0.14 1.57E-05 ¡0.86
cg18261223 5 32711517 NPR3 0.14 2.76E-06 ¡1.01
cg09435090 4 17513980 QDPR 0.14 1.17E-06 ¡0.86
cg20684973 10 105127632 TAF5 0.14 5.18E-08 ¡1.06
cg00565558 7 6120396 0.14 2.07E-08 ¡0.82
cg23802518 10 80827482 ZMIZ1 0.14 2.47E-07 ¡0.91
cg18036763 22 45404910 PHF21B 0.13 9.57E-08 ¡0.84
cg08965527 16 84178213 HSDL1;LRRC50 0.13 6.78E-08 ¡0.83
cg10861135 9 14345348 0.13 3.31E-07 ¡0.91
cg00510787 6 151772946 C6orf211;RMND1 0.13 2.03E-06 ¡0.78
cg09747578 1 46769076 LRRC41;UQCRH 0.12 9.43E-08 ¡0.89
cg18022926 10 70093071 PBLD;HNRNPH3 0.12 1.24E-07 ¡0.88
cg10013169 6 5997028 0.12 1.98E-06 ¡0.86
cg22276571 20 17549599 DSTN;DSTN 0.12 4.88E-07 ¡0.77
cg16595484 3 122512170 HSPBAP1 0.12 1.25E-06 ¡0.71
cg03393426 10 102986686 0.12 1.07E-07 ¡0.86
cg04921814 1 145575587 PIAS3 0.12 2.26E-06 ¡0.87
cg21935083 5 131892314 RAD50 0.12 5.42E-07 ¡0.64
cg23653187 22 44319257 PNPLA3 0.12 8.65E-07 ¡0.88
cg17344340 22 46044084 0.11 7.95E-06 ¡0.68
cg07772516 15 52107742 TMOD2;TMOD2 0.11 6.76E-06 ¡0.67
cg08779777 7 106505772 PIK3CG 0.11 2.62E-05 ¡0.72
cg21860429 6 105389544 0.11 2.19E-05 ¡0.67
cg14555127 7 35841578 SEPT7; 0.11 4.86E-07 ¡0.76
cg04609859 17 46655736 HOXB4 0.11 1.45E-06 ¡0.77
cg21312090 8 116681727 TRPS1 0.11 2.44E-06 ¡0.74
cg17373554 5 72594735 0.11 1.88E-05 ¡0.67
cg05489143 3 40498640 RPL14 0.11 8.96E-07 ¡0.81
cg04005701 17 1733641 RPA1;SMYD4 0.11 1.87E-07 ¡0.70
cg20760063 17 41277580 NBR2;BRCA1 0.11 4.40E-08 ¡0.85
cg06361531 16 68057779 DUS2L;DDX28 0.11 2.72E-07 ¡0.69
cg01013600 19 49141177 DBP;SEC1 0.11 3.42E-07 ¡0.71
cg25845597 6 27841122 HIST1H4L;HIST1H3I 0.11 2.00E-07 ¡1.08
cg14036868 2 38604442 ATL2 0.11 7.45E-07 ¡0.95
cg26220528 12 57623348 SHMT2 0.11 5.92E-07 ¡0.80
cg01147107 1 47696505 TAL1 0.11 5.12E-07 ¡0.70
cg16942681 18 21032779 RIOK3 0.11 6.05E-05 ¡0.74
cg08215925 3 71633214 FOXP1 0.11 1.02E-05 ¡0.98
Table 2b. Table shows the most hypomethylated DMPs (b value >¡10%) in umbilical cord blood from FGR compared with AGA offspring. Columns show
CG identifying site, chromosome number, chromosome coordinate, gene identiﬁer, chromosome number, methylation b value, and adjusted P value for dif-
ference in mean b value between FGR and AGA offspring and M value
ID CHR MAPINFO UCSC Ref Gene b value P value M value difference
cg23372001 6 27791640 HIST1H4J ¡0.22 1.10E-10 1.83
cg26758857 22 36649135 APOL1 ¡0.18 3.47E-07 1.18
cg05533953 4 331685 ZNF141 ¡0.15 1.69E-10 1.45
cg26542283 5 43040505 C5orf39 ¡0.15 2.77E-09 1.66
cg07875360 5 1801344 NDUFS6;MRPL36 ¡0.13 4.60E-08 0.95
ch.20.327316F 20 15628644 MACROD2 ¡0.12 8.34E-10 0.74
cg01458605 3 147128679 ZIC1 ¡0.11 4.69E-10 1.00
cg04410715 19 39283334 ¡0.11 2.53E-08 0.83
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value -0.15) within 7 and 24 base pairs of 2 C5orf39 SNPs and one
hypermethylated site (b value C0.14) within 47 base pairs of a
TAF5 gene variant.
Furthermore, within the 839 DMPs found in umbilical
cord blood between FGR and AGA at term, we did not
observe the methylation pattern typically associated with
SNPs (0%, 50%, or 100%). It is also of note that cord blood
and placenta are of fetal origin and share the same genotype,
but we found no overlap in DMPs between these tissues.
Taken together, these observations suggest that the methyla-
tion differences between FGR and AGA offspring that we
found are unlikely to be driven by SNPs.
Functional pathways of DMPs discovered in cord blood
between FGR and AGA offspring using the Marmal-aid
database
The Marmal-aid DNA methylation database, which contains
>10,000 samples in one repository,25 was used to gain insight
into the functionality of the 839 differentially methylated CpG
sites that we discovered in cord blood from FGR offspring born
at term. The Marmal-aid output suggested that the 839 DMPs
are found in normally very stable unmethylated or hypomethy-
lated gene loci consistent across all blood cell types. Also, these
same positions vary little in methylation status between tissue
type and through aging and are located in highly conserved,
invariate regions of the genome.
To establish whether the 839 term DMPs linked to Ref Seq-
annotated genes had significant functional roles, we used GO
pathway analysis. Using an R based package and thresholds
described in the materials and methods section, 23 GO pathways
were identified (Table 3). Many of these pathways contained
DMPs with >10% b value differences between FGR and AGA
offspring, supporting a potential functional role for these DMPs.
The majority of pathways identified through GO analysis related
to regulation of gene transcription and expression and control of
metabolic processes. Pathways with the greatest methylation
Table 3. Twenty-three GO pathways identiﬁed using 839 DMPs within FGR term umbilical cord blood samples. Fold change refers to the number of DMP on
genes actually present in the pathway compared with the number expected and that met the P-value < 0.0001 and cut off of 2-fold change (rounded up).
The last 2 columns report the most differentially methylated genes (>10 %) found in the respective GO pathway.
Gene in pathway >10% b value difference
GO term Fold change Hypermethylated Hypomethylated
DNA recombination 3.05 IL27RA, FOXB1, RAD50
cellular process 2.6 RIOK3; IL27RA; RIT1; JARID2; TAF5; RAD50; HOXB4;
TRPS1; RPL14; ATL2; FOXP1
APOL1; ZNF141; MACROD2; ZIC1
regulation of transcription from RNA
polymerase II promoter
2.32 JARID2; HOXB4;TRPS1; FOXP1
transcription from RNA polymerase II
promoter
2.23 JARID2; TAF5; HOXB4; TRPS1; FOXP1 ZNF141
embryo development 2.15 HOXB4; FOXP1 ZIC1
central nervous system development 2.15 JARID2; FOXP1 ZIC1
positive regulation of transcription from RNA
polymerase II promoter
2.09 FOXP1
regulation of nucleobase-containing
compound metabolic process
2.03 IL27RA; JARID2; TAF5; RAD50; HOXB4; FOXP1 ZNF141; ZIC1
negative regulation of nucleobase-
containing compound metabolic process
2.01 JARID2; HOXB4; FOXP1
regulation of nitrogen compound metabolic
process
2.00 IL27RA; JARID2; TAF5; HOXB4; TRPS1; FOXP1 ZNF141; ZIC1
RNA biosynthetic process 2.00 TRPS1; FOXP1 ZIC1
negative regulation of gene expression 1.99 JARID2; HOXB4; TRPS1; FOXP1
negative regulation of cellular
macromolecule biosynthetic process
1.99 JARID2; HOXB4; TRPS1; FOXP1
regulation of cellular macromolecule
biosynthetic process
1.98 JARID2; HOXB4; TRPS1; FOXP1 ZNF141; ZIC1
regulation of transcription, DNA-dependent 1.98 JARID2; TAF5; HOXB4; TRPS1; FOXP1 ZNF141; ZIC1
negative regulation of nitrogen compound
metabolic process
1.98 IL27RA; JARID2; TAF5; HOXB4;TRPS1; FOXP1 ZNF141; ZIC1
regulation of gene expression 1.97 ZIC1; ZNF141; HOXB4; FOXP1; JARID2; TAF5 ZNF141; ZIC1
transcription, DNA-dependent 1.97 JARID2; TAF5; HOXB4; FOXP1 ZNF141; ZIC1
regulation of RNA biosynthetic process 1.97 JARID2; TAF5
organ morphogenesis 1.97 HOXB4; FOXP1 ZIC1
nucleic acid metabolic process 1.96 IL27RA; JARID2; TAF5; HOXB4; FOXP1 ZNF141; ZIC1
regulation of macromolecule biosynthetic
process
1.96 JARID2; TAF5; HOXB4; FOXP1 ZNF141; ZIC1
negative regulation of macromolecule
biosynthetic process
1.96 JARID2; HOXB4; TRPS1; FOXP1
regulation of RNA metabolic process 1.96 JARID2; TAF5 ; HOXB4; FOXP1 ZNF141; ZIC1
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difference were involved in the regulation and transcription of
RNA polymerase II.
Placental DMPs between FGR and AGA offspring
In the placenta from term deliveries, there were no DMPs
between FGR and AGA offspring that reached genome-wide sig-
nificance. To elucidate whether the 453 placental DMPs initially
identified between FGR and AGA offspring were primarily
driven by differences in gestational age, we ran a linear model on
all placental samples using gestational age as a continuous vari-
able across the gestational age range (202 to 299 days). We iden-
tified 20,893 placental DMPs associated with gestational age,
heavily influenced by placentae from early gestational FGR preg-
nancies. The majority of placental DMPs were hypomethylated
(93%), but with advancing gestation the placenta became more
methylated (adjusted P < 0.05), consistent with the findings of
others.17
We validated placental results using methylation data from
a study of placental tissue from healthy pregnancies, across all
3 trimesters and run on an Illumina HumanMethylation27
BeadChip, a precursor of the 450K array.17 Using the same
cutoff for statistical significance as our study (FDR-adjusted
P < 0.05) we identified placental DMPs between the second
trimester and term groups in the published data set17 and
searched for similar placental DMPs between the second tri-
mester and term in our own cohort. Out of 23,677 positions
available for direct comparison between the 27K and 450K
platforms, 825 DMPs were called from these positions using
the 450K analysis and of these, 541 (65%) were also identified
using the 27K analysis.17 Both data sets
contained 519 similarly hypomethylated
and 13 similarly hypermethylated posi-
tions. Only 9 probes showed methylation
in opposite directions (Fig. 3). The
remaining 284/825 DMPs unique to our
FGR cases have the potential to have a
role in fetal growth independent of gesta-
tional age. GO pathway analysis of these
284 placental DMPs showed 16 pathways
that met the criteria for reporting. These
included pathways involved in the regula-
tion of autophagy, response to oxidative
stress and hormonal stimuli (Table 4).
Discussion
We found that cord blood from new-
born offspring affected by fetal growth
restriction (FGR) had significant DNA
methylation differences compared with
appropriately grown offspring (AGA).
Methylation differences persisted after
accounting for differences in gestational
age and were consistent across leucocyte
populations in umbilical cord blood.
DMPs were associated with genes involved in pathways crucial to
key cellular processes, particularly regulation of gene expression
and transcription. Several of the 53 DMPs with the greatest
methylation differences were methylated at more than one CpG
site, emphasizing the potential for methylation differences to
influence gene expression.
Three of the most differentially methylated positions between
FGR and AGA cord blood were co-methylated at several CpG
sites on genes that control ubiquitous transcription factors.
FOXP1, which was hypermethylated at 3 CpG sites, is expressed
in many tissues and is important for organogenesis, metabolism,
and immunity.29 RIOK3 was hypermethylated on 2 CpG sites
just 5 base pairs apart (b values C11% and C17%). RIOK3 is an
atypical protein kinase that interacts with caspase-10 and nega-
tively regulates NF-Kappa B.30 Inhibition of NF-Kappa B
reduces angiogenesis, but permits apoptosis with the potential to
compromise fetal growth and development.31 TAF5 encodes a
key subunit that is critical to the formation of basal transcription
factor, Transcription Initiation Factor TFIID subunit 5
(TFIID).32 TFIID is used by RNA polymerase II for transcript
initiation and is critical for reprogramming of pluripotent embry-
onic stem cells.33 Enhanced expression of TFIID during fetal life
may therefore generate plasticity in gene expression that could
influence embryonic stem cells to pass into different cellular
states. RNA polymerase II pathways also featured heavily in our
GO analysis of term DMPs in cord blood from FGR offspring.
Epigenetic interference with the expression of these transcription
factors has the potential for far reaching effects during a time of
developmental plasticity.
Figure 3. Placental DMPs between 2nd and 3rd trimesters in our data set using the Inﬁnium
HumanMethylation450 Beadchip and also present in an external data set using the Inﬁnium
HumanMethylation27.17 There were 519 hypomethylated DMPs common to both platforms
(yellow), 13 hypermethylated DMPs common to both platforms (blue) and 9 DMPs that were
mismatched with regards direction of methylation (red).
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A minority of DMPs on genes from FGR cord blood were
hypomethylated compared with AGA offspring. Gene variants of
APOL1, which we found to be hypomethylated (b value, ¡18%)
are associated with accelerated kidney disease and lower HDL
concentrations, especially in African Americans.34,35 Methylation
differences on APOL1 were also found in cord blood mononu-
clear cells in twins and correlate with birth weight.36 Interest-
ingly, a near neighbor of APOL1 on chromosome 22 is PNPLA3,
which we found to be hypermethylated (b value C0.12). Gene
variants of PNPLA3 produce excess adiponutrin, which promotes
lipid synthesis and increases the risk of non-alcoholic fatty liver
disease.37
We also found hypomethylation on C5orf39 (b value -15%
and co-methylated in 4 positions) is a gene unique to humans
that encodes Annexin II receptor, a novel activator of apoptosis.38
Low birth weight offspring show increased lymphocyte apoptosis,
which correlates with insulin resistance.39
Genes that encode histone proteins were found to be differen-
tially methylated in both directions, HIST1H4J (b value ¡22%)
and HIST1H3I (b value C11%). There were 7 DMPS regulating
histone modification, which may suggest a role for epigenetic
events other than DNA methylation influencing gene expression
in FGR offspring. Histone modification, which most often
involves post-translational changes to the tail of a histone protein,
influences transcription of the associated gene and has a role in
human development.40 Cellular pluripotency during fetal life is
partly determined by histone modification and therefore factors
that influence histone gene expression may play an important
role in this critical element of fetal development.41
Umbilical cord blood from over 1000 infants in the Norwe-
gian Mother and Child Cohort assessed using the Infinium
HumanMethylation450 BeadChip showed differential methyla-
tion at 19 CpGs associated with either increased or decreased
birth weight across a range of normal birth weights.42 Two genes,
ARID5B and XRCC3, were particularly associated with either
decreased or increased birth weight, respectively. These genes did
not appear among the strongly differentially methylated genes in
our cohort of pathologically growth restricted offspring. It is pos-
sible that the influence of DNA methylation is different within a
spectrum of healthy birth weight offspring as compared with
pathological growth restriction.
We studied well-phenotyped FGR offspring identified in
utero according to customized fetal growth scales in otherwise
healthy mothers and in the absence of other fetal disease. In all
but 1 of the 29 cases for whom we have data, there was elevated
utero-placental perfusion pressures with poor placental perfusion,
before the identification of FGR. In an animal model that
mimics human fetal growth restriction by ligating both uterine
arteries, epigenetic dysregulation was seen at conserved intergenic
sequences in 7-week old offspring.43 These epigenetic events
were near genes that regulate vascularization, pancreatic b cell
proliferation, and apoptosis, which may underpin the vulnerabil-
ity of FGR offspring to type-2 diabetes.33 Similarities between
this animal model and the placental driven FGR in our cases,
supports the concept that the methylation differences seen in
FGR offspring are secondary to reduced utero-placental
perfusion.
Animal models have also shown that maternal and paternal
diet can alter offspring phenotype through epigenetic mecha-
nisms.44,45 We studied FGR offspring from well-nourished
mothers who had a similar phenotype to mothers of AGA off-
spring, but in whom there was poor placental development.
Interestingly, we found sub-clinical insulin resistance in the
fathers of FGR pregnancies, as we previously reported.46 We
did not assess the paternal epigenome, but animal studies sup-
port the possibility that paternal diet-induced epigenetic
Table 4. GO pathway analysis of 284 placental DMPs associated with our FGR cohort. These DMPs were identiﬁed after validation analysis with an external
data set of placentas from healthy pregnancies across 3 trimesters.17 After excluding DMPs that were present on both platforms and assumed to be associ-
ated with gestational age, the remaining 284 DMPs remained unique to our FGR cohort. Sixteen functional pathways met the criteria for reporting. Pathways
known to be associated with fetal growth restriction and that were evident in the placenta of our FGR cohort included autophagy, response to oxidative
stress and the regulation of monocyte chemotaxis. The actual and expected number of DMPs on genes in the pathway is recorded and the fold change
between these counts that met the P-value<0.0001 and cut off of >2-fold change
GOBPID Fold change Exp count Actual count GO Term
GO:0016239 31.4 0.14 3 positive regulation of macroautophagy
GO:0090026 31.4 0.14 3 positive regulation of monocyte chemotaxis
GO:0010508 16.8 0.3 4 positive regulation of autophagy
GO:0032312 12 0.4 4 regulation of ARF GTPase activity
GO:0010506 9.78 0.72 6 regulation of autophagy
GO:0006914 5.12 1.49 7 autophagy
GO:0043627 4.24 2.31 9 response to estrogen stimulus
GO:0006979 4.08 3.5 13 response to oxidative stress
GO:0031667 3.06 5.31 15 response to nutrient levels
GO:0032870 3.05 6.07 17 cellular response to hormone stimulus
GO:0043434 3.05 5.71 16 response to peptide hormone stimulus
GO:0051270 2.85 6.07 16 regulation of cellular component movement
GO:0009991 2.85 5.68 15 response to extracellular stimulus
GO:0009725 2.49 10.6 24 response to hormone stimulus
GO:0071495 2.46 8.35 19 cellular response to endogenous stimulus
GO:0032879 2.04 18.4 34 regulation of localization
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change can be inherited by offspring and lead to reduced fetal
growth.45 It is also possible that gene variants that predispose
the father to insulin resistance are inherited by offspring.
Under these circumstances, insulin cannot act as an effective
growth factor in utero and predisposes the fetus to diabetes in
later life.47
To date, the study of rare imprinted gene disorders has shown
an influential role for altered methylation of genes essential to
fetal growth.19,48 Our study has taken a broader, unbiased
whole-genome approach to identify methylation changes on
genes of FGR offspring secondary to poor placental develop-
ment. In our cases, we found low-level methylation differences in
2 imprinted genes Plagl and Kcnq1, but despite good coverage in
the HM450 data set, we found no differences in methylation of
Igf2/H19. Our study suggests that imprinted genes have little
influence on FGR secondary to poor placental development, but
rather genes encoding key transcription factors are differentially
methylated. Future studies might investigate the parent of origin
of these novel regions of differential methylation.
Fetal growth restriction often results in iatrogenic prema-
ture childbirth, secondary to failure of the fetus to thrive in
utero. This leads to the dual problems of low birth weight
and prematurity. In our study we dissected apart the influ-
ence of gestational age from impaired fetal growth by match-
ing FGR cases that delivered at term with the AGA offspring
and by excluding DMPs associated with increasing gestational
age. We also compared our placental methylation results with
a published data set.17 Although we showed methylation sta-
tus of the placenta and cord blood altered with advancing
gestational age, we identified DMPs that remained unique to
FGR offspring. Further investigation of the effects of these
DMPs on placental gene function is necessary to understand
how they might influence fetal growth and predispose to dis-
ease in later life.
In placentas of pre-term FGR offspring, GO pathway analysis
identified differential methylation on genes implicated in path-
ways important to oxidative stress, hormonal stimulation, and
autophagy. These pathways are crucial to normal placental devel-
opment, while abnormal autophagy and oxidative stress are rec-
ognized features of FGR placentas.49-51
At term, we did not observe methylation differences between
the placentas from FGR and AGA that were evident in earlier
pregnancy. It is possible that given time, pathological differences
in the placental methylome that influence fetal growth give way
to gestational influences in anticipation of childbirth. Differences
in placental methylation in pregnancies destined to result in fetal
growth restriction appear to be more pronounced in early
pregnancy.
The Infinium HumanMethylation27 BeadChip platform,
was previously used on 206 term placentas and identified 22
methylation loci that could act as markers for poor fetal
growth.52 Notably, placentas from growth restricted (FGR) and
constitutionally small offspring (SGA) were combined in this
analysis.52 Although we did not replicate methylation loci using
the Infinium HumanMethylation450 BeadChip with this
cohort, methylation differences on pathways associated with basic
cellular functions including transcription and DNA repair52 were
similar to those we found in pre-term placentas. However, 6 of
the 22 DMPs in the FGR and SGA cohort combined52 were
present in the second and third trimester of the external placental
dataset,17 supporting a possible influence of these loci on gesta-
tional age.
Placentas from pregnancies affected by pre-term preeclampsia,
a condition that shares very similar placental characteristics to
FGR pregnancies,53 have been found to have distinct methyla-
tion profiles using the 450 BeadChip.54 However, no further dif-
ferences in placental methylation were found according to
whether the preeclamptic pregnancies were also affected by FGR
or AGA offspring.54 The differences we found in methylation
profile in umbilical cord blood between FGR and AGA suggests
that the fetal response to the same placental pathology is distinc-
tive for those who cannot grow to their full potential.
Placentas from monochorionic twins discordant for fetal
growth, have shown increased DNA methylation of the leptin
promoter region and upregulation of leptin mRNA in the smaller
twin.55 Similarly, expression of LEPROT1 (Leptin receptor over-
lapping transcript-like 1) from cord blood mononuclear cells of
dichorionic twins showed a negative correlation with birth
weight.56 These observations may explain the future vulnerability
of low birth weight offspring to metabolic syndrome. However,
we did not find any DMPs associated with leptin that reached
genome wide significance between FGR and AGA placentae.
Although there was no difference in the mode of delivery of
FGR and AGA offspring born at term, the mode of delivery has
been shown to influence offspring methylation status.57 Off-
spring born by caesarean section have higher DNA methylation
in umbilical cord blood leucocytes compared with those born by
vaginal delivery.57 Interestingly, methylation differences associ-
ated with mode of delivery did not persist when re-examined in
neonatal leucocytes 3–5 d postpartum.57 It is possible that tran-
sient environmental exposure such as mode of delivery causes
short-lived epigenetic changes, while persistent environmental
influences during a time of high developmental plasticity in
utero, cause more enduring effects.
A potential limitation of our study was that we assessed DNA
methylation in umbilical cord whole blood at birth, while fetal
circulating cell types change according to birth weight and gesta-
tion at delivery.58 However, at term nucleated red blood cells
comprise a small percentage of total cell number (3 per 100
wbcs), which limits their influence on the methylation of cells
from cord blood.59 Furthermore, according to the Marmal-aid
data set, we showed a similar pattern of DMPs in areas normally
unmethylated and across cord blood cell types. Differences in cell
type that might exist at term between FGR and AGA are unlikely
to play a significant role in observed DMPs.26 Cell composition
is however likely to explain some of the 76,249 DMPs that we
identified in cord blood of pre-term FGR offspring.
Despite many human studies investigating genetic and envi-
ronmental mechanisms that might link low birth weight with
risk of adult disease, there is very little reproducible evidence to
support a unifying pathophysiological process. This may partly
reflect the multi-factorial elements that lead to FGR as well as
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subsequent environmental influences that promote vulnerability
to polygenic disease, such as type-2 diabetes mellitus (T2DM).
Although gene variants can have pleiotropic effects on different
organs, organ specific diseases need to be investigated using the
relevant tissue. In this regard, the study of the placenta is relevant
to fetal growth restriction, but the study of less accessible tissue,
such as the pancreas, is needed to investigate the metabolic syn-
drome or T2DM. Altered methylation status of selected candi-
date genes from umbilical cord tissue has however been
correlated with later life phenotype.12 Conversely, saliva from
monozygotic monochorionic twins aged 34 years, showed very
similar genome-wide DNA methylation profiles between twins
that were discordant for birth weight.15
The novel cord blood DMPs in well-phenotyped FGR off-
spring that we observed warrant further targeted study that might
provide a pathophysiological link between low birth weight and
adult disease. DMPs in FGR cord blood may be a consequence
of placental dysfunction or inherited from insulin resistant
fathers. Reassessment of FGR neonates in adulthood would
determine if DMPs identified at birth have endured into later life
to influence vulnerability to adult disease.
Patients and Methods
Selection of cases and controls
A case-control collection of samples from pregnancies affected
by fetal growth restriction and appropriately grown offspring was
undertaken at University College London Hospital (UCLH)
between September 2009 and May 2011. The Joint UCLH/
UCL (a) Ethical Committee (09/H0715/28) granted ethical
approval for the study. All participants gave informed consent.
Caucasian women were included as cases when an ultrasound
scan identified fetal growth restriction (FGR), defined as an esti-
mated fetal weight <10th customized centile for gestational age
and adjusted for maternal weight, height, parity, and ethnicity
(available from Perinatal Institute, UK - www.gestation.net).
Pregnancies were excluded if fetal growth restriction was associ-
ated with fetal structural or chromosomal abnormalities, infec-
tions, chronic maternal disease, or multiple pregnancies.
Pregnant women were included in the control group if they were
found to have an appropriately grown for gestational age (AGA)
fetus, with an estimated fetal weight between 10th and 95th cus-
tomized centile, born at more than 255 d and only if predicted
normal fetal growth matched neonatal measures after delivery.
After a diagnosis of FGR, we examined case notes for informa-
tion on uterine artery blood flow at 20–22 week gestation.
At childbirth, umbilical cord blood was taken from the umbil-
ical vein, and stored at ¡80oC. Placental samples were taken
from the fetal surface within 2 cm of the cord insertion and
stored at ¡80C. Gestational age, offspring gender, weight,
length, and delivery details were recorded.
Within 4 weeks of childbirth, paternal phenotype was also
assessed. Specifically, we measured paternal blood pressure, waist
circumference, fasting glucose and insulin levels.
DNA extraction
DNA was extracted from paired placenta and cord blood sam-
ples using standard kits and protocols (DNeasy Blood & Tissue
Kit, Qiagen, UK). After cleanup (DNA Clean & Concentrator
Kit, Zymo Research, Cambridge Biosciences, UK), samples with
a 260/280 ratio >1.75 and a 260/230 ratio >1.8 were discarded
from further analysis.
Bisulphite conversion
High-quality genomic DNA (500ng) was bisulphite converted
using the EZ-96 DNA Methylation Deep-well Kit (Zymo
Research, Cambridge Biosciences, UK). Bisulphite conversion
efficiency was assessed using qPCR with primers to converted
and non-converted DNA (Primers and cycling parameters in
appendix) and samples that showed <97% bisulphite conversion
were excluded. A total of 56 cord blood and 54 placental samples
were suitable for methylation analysis, including 49 participants
with both cord blood and placental samples and 12 further tissue
samples (7 cord blood and 5 placenta).
Illumina human methylation450 beadChip
Bisulphite-converted samples were hybridized to the Illumina
HumanMethylation450 BeadChip (Illumina, Inc., CA, USA)60
using standard protocols. Cases and controls and tissue type were
arranged randomly on each chip and processed in a blinded fash-
ion. Arrays were scanned using the Illumina iScan SQ 2-color
laser scanner.
Quality Control
We evaluated the quality of the data based on the signals of
control probes built in to the assay. This resulted in 90 samples
that were suitable for downstream analysis. Multiple Dimen-
sional Scaling analysis (MDS) demonstrated no significant posi-
tional or chip batch effect between samples.
Quantile normalization was performed separately for individ-
ual color channels, probe types, and tissue types (cord blood and
placenta) due to their variable distribution of methylation values
(b values). Probe b values (methylated probe intensity/[methyl-
ated probe intensity C unmethylated probe intensity C 100])
were converted to M-values by Logit transformation to reduce
heteroscedasticity.27
Of 486,428 probes present on the array, 11,648 X and Y
chromosome probes were removed; 1,927 were removed for fail-
ing to meet the detection P-value cut-off (PD 0.05) and a further
43,097 were removed due to probe cross-hybridization. This
resulted in a total of 429,756 probes, representing individual
positions of methylation available for downstream analysis.
Statistical Analysis
The influence of gestational age on DMPs between FGR and
AGA was assessed using a continuous linear regression model in
the Limma package, incorporating all samples and gestational
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age. Results were validated against an external data set of placen-
tal tissue from AGA pregnancies that were investigated using the
Illumina 27K methylation array.17
To further characterize the DMPs, we utilized Marmal-aid
(http://marmal-aid.org),25 a recently developed meta-analysis
tool. In Marmal-aid, all publicly available Illumina 450K data
(>10,000 different arrays as of June, 2013) is incorporated into a
single repository and re-processed to enable customizable meta-
analyses.
GO pathway analysis was also performed in order to deduce
gene function of identified DMPs. We only reported those path-
ways that had a 2-fold (rounded up) enrichment of genes more
than expected and that reached a significant P-value of <0.0001.
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